AU2023208408A1 - Complexes for cancer treatment and imaging - Google Patents
Complexes for cancer treatment and imaging Download PDFInfo
- Publication number
- AU2023208408A1 AU2023208408A1 AU2023208408A AU2023208408A AU2023208408A1 AU 2023208408 A1 AU2023208408 A1 AU 2023208408A1 AU 2023208408 A AU2023208408 A AU 2023208408A AU 2023208408 A AU2023208408 A AU 2023208408A AU 2023208408 A1 AU2023208408 A1 AU 2023208408A1
- Authority
- AU
- Australia
- Prior art keywords
- radionuclide
- present
- complex according
- pharmaceutical composition
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 40
- 238000003384 imaging method Methods 0.000 title claims description 31
- 201000011510 cancer Diseases 0.000 title claims description 21
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 50
- -1 111ln Chemical compound 0.000 claims description 31
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 230000003211 malignant effect Effects 0.000 claims description 18
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 238000002600 positron emission tomography Methods 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 9
- 239000012217 radiopharmaceutical Substances 0.000 claims description 9
- 229940121896 radiopharmaceutical Drugs 0.000 claims description 9
- 230000002799 radiopharmaceutical effect Effects 0.000 claims description 9
- 210000003734 kidney Anatomy 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 238000003325 tomography Methods 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract description 37
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract description 24
- 230000008685 targeting Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 description 16
- 239000002287 radioligand Substances 0.000 description 16
- 230000027455 binding Effects 0.000 description 13
- WABPQHHGFIMREM-BKFZFHPZSA-N lead-212 Chemical compound [212Pb] WABPQHHGFIMREM-BKFZFHPZSA-N 0.000 description 13
- 239000003446 ligand Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 101710183768 Glutamate carboxypeptidase 2 Proteins 0.000 description 9
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000009206 nuclear medicine Methods 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 210000004872 soft tissue Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000003278 mimic effect Effects 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 2
- 206010027452 Metastases to bone Diseases 0.000 description 2
- 108010037516 PSMA-617 Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008139 complexing agent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- JBHPLHATEXGMQR-LFWIOBPJSA-N vipivotide tetraxetan Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC=C2C=CC=CC2=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O JBHPLHATEXGMQR-LFWIOBPJSA-N 0.000 description 2
- RWRDJVNMSZYMDV-SIUYXFDKSA-L (223)RaCl2 Chemical compound Cl[223Ra]Cl RWRDJVNMSZYMDV-SIUYXFDKSA-L 0.000 description 1
- UDOPJKHABYSVIX-UHFFFAOYSA-N 2-[4,7,10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN(CC(O)=O)C1CC1=CC=C(N=C=S)C=C1 UDOPJKHABYSVIX-UHFFFAOYSA-N 0.000 description 1
- VVDALGFFYBSXSQ-UHFFFAOYSA-N 2-[6-benzyl-4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1N(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN(CC(O)=O)C1CC1=CC=CC=C1 VVDALGFFYBSXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101001058904 Homo sapiens Gamma-tubulin complex component 2 Proteins 0.000 description 1
- 101001014636 Homo sapiens Golgin subfamily A member 4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 108050003189 SH2B adapter protein 1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- LBDSXVIYZYSRII-IGMARMGPSA-N alpha-particle Chemical compound [4He+2] LBDSXVIYZYSRII-IGMARMGPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000000693 radiobiological effect Effects 0.000 description 1
- 238000003608 radiolysis reaction Methods 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 229910052705 radium Inorganic materials 0.000 description 1
- HCWPIIXVSYCSAN-UHFFFAOYSA-N radium atom Chemical compound [Ra] HCWPIIXVSYCSAN-UHFFFAOYSA-N 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000002602 scintillography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940066799 xofigo Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22152725.2 | 2022-01-21 | ||
| EP22152725 | 2022-01-21 | ||
| PCT/EP2023/051355 WO2023139203A1 (en) | 2022-01-21 | 2023-01-20 | Complexes for cancer treatment and imaging |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023208408A1 true AU2023208408A1 (en) | 2024-08-01 |
Family
ID=79927204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023208408A Pending AU2023208408A1 (en) | 2022-01-21 | 2023-01-20 | Complexes for cancer treatment and imaging |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250099631A1 (https=) |
| EP (1) | EP4466032A1 (https=) |
| JP (1) | JP2025503096A (https=) |
| CN (1) | CN118891066A (https=) |
| AU (1) | AU2023208408A1 (https=) |
| WO (1) | WO2023139203A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200297877A1 (en) | 2017-12-13 | 2020-09-24 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200297877A1 (en) * | 2017-12-13 | 2020-09-24 | Sciencons AS | Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide |
| EP3856261A1 (en) * | 2018-09-28 | 2021-08-04 | Universität Heidelberg | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers |
-
2023
- 2023-01-20 WO PCT/EP2023/051355 patent/WO2023139203A1/en not_active Ceased
- 2023-01-20 US US18/729,758 patent/US20250099631A1/en active Pending
- 2023-01-20 EP EP23701666.2A patent/EP4466032A1/en active Pending
- 2023-01-20 CN CN202380027967.6A patent/CN118891066A/zh active Pending
- 2023-01-20 AU AU2023208408A patent/AU2023208408A1/en active Pending
- 2023-01-20 JP JP2024543372A patent/JP2025503096A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023139203A1 (en) | 2023-07-27 |
| JP2025503096A (ja) | 2025-01-30 |
| CN118891066A (zh) | 2024-11-01 |
| US20250099631A1 (en) | 2025-03-27 |
| EP4466032A1 (en) | 2024-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Long et al. | Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms | |
| Cook et al. | Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG | |
| Sainz-Esteban et al. | Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy | |
| Kvols et al. | Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors. | |
| Fröberg et al. | Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma | |
| Alsharef et al. | Review about radiopharmaceuticals: preparation, radioactivity, and applications | |
| Zhu et al. | Biodistribution and radiation dosimetry of the Enterobacteriaceae-specific imaging probe [18F] fluorodeoxysorbitol determined by PET/CT in healthy human volunteers | |
| Ahmed et al. | Diagnostic modalities and radiopharmaceuticals with particular importance of technetium-99m (99mTc) | |
| Ortiz-Arzate et al. | Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c (RGDfK)] 2 for breast cancer imaging | |
| Montilla-Soler et al. | Skeletal scintigraphy | |
| Ilem-Ozdemir et al. | Nuclear medicine and radiopharmaceuticals for molecular diagnosis | |
| Leichner et al. | Patient-specific dosimetry of indium-111-and yttrium-90-labeled monoclonal antibody CC49 | |
| Knapp et al. | Introduction: radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine | |
| AU2023208408A1 (en) | Complexes for cancer treatment and imaging | |
| Kaur et al. | Theranostics: New era in nuclear medicine and radiopharmaceuticals | |
| Orsini et al. | Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications | |
| US10363324B2 (en) | Pharmaceutical composition | |
| Shahzad et al. | A new method for synthesis of 99mTc-enorfloxacin: An infection imaging agent | |
| Gholipour et al. | Chelator-free radiolabeling of dextran with 68Ga for PET studies | |
| Das et al. | Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: A comparison with ‘in-situ’preparation at hospital radiopharmacy | |
| Workman Jr et al. | Fundamentals of PET and PET/CT imaging | |
| Saleh | Technetium-99m radiopharmaceuticals | |
| JP4863345B2 (ja) | 心筋用放射性画像診断剤又は放射性治療薬 | |
| Rizvi et al. | In-house production of [99mTc][Tc-HYNIC-TATE] cold kit for the diagnosis of neuroendocrine tumors in Pakistan: pre-clinical and clinical evaluation of indigenously manufactured single and dual vial kit formulation | |
| Cullen et al. | Tutorial 14: Introduction to Nuclear Medicine |